Exelixis
EXEL
#2208
Rank
$5.41 B
Marketcap
$16.79
Share price
-0.89%
Change (1 day)
-1.58%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2022 (TTM): $2.14 B

According to Exelixis's latest financial reports the company's current revenue (TTM) is $2.14 B. In 2021 the company made a revenue of $1.81 B an increase over the years 2020 revenue that were of $1.20 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2001 to 2022

Annual revenue

Year Revenue Change
2022 (TTM)$2.14 B18.21%
2021$1.81 B49.81%
2020$1.20 B24.88%
2019$0.96 B13.53%
2018$0.85 B88.4%
2017$0.45 B136.34%
2016$0.19 B415.05%
2015$37.17 M52.14%
2014$24.43 M-22.03%
2013$31.33 M-33.96%
2012$47.45 M-83.62%
2011$0.28 B56.52%
2010$0.18 B21.93%
2009$0.15 B28.76%
2008$0.11 B3.87%
2007$0.11 B15%
2006$98.67 M29.9%
2005$75.96 M43.71%
2004$52.85 M2.56%
2003$51.54 M16.24%
2002$44.34 M8.13%
2001$41 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
$96.04 B 4,387.32%๐Ÿ‡บ๐Ÿ‡ธ USA
$99.67 B 4,557.16%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.52 B 1,045.65%๐Ÿ‡บ๐Ÿ‡ธ USA
$44.95 B 2,000.35%๐Ÿ‡ซ๐Ÿ‡ท France
$58.97 B 2,655.44%๐Ÿ‡บ๐Ÿ‡ธ USA
$45.99 B 2,049.07%๐Ÿ‡บ๐Ÿ‡ธ USA
$42.86 B 1,902.57%๐Ÿ‡ฌ๐Ÿ‡ง UK
$10.74 M-99.50%๐Ÿ‡บ๐Ÿ‡ธ USA
$94.31 M-95.59%๐Ÿ‡บ๐Ÿ‡ธ USA